Anti-Aging & Telomere Peptide Reference

Epitalon (Ala-Glu-Asp-Gly) has been shown to activate telomerase in human somatic cell cultures in vitro, extending the replicative lifespan of fibroblasts and retinal pigment epithelial cells. The in vivo human evidence comes from Khavinson's group in Russia — small studies showing telomere lengthening in elderly subjects — but these have not been independently replicated by Western research groups. The mechanism is plausible; the clinical evidence is preliminary.

SS-31 (Elamipretide) has the strongest clinical development pipeline — Phase 2/3 trials for Barth syndrome and age-related mitochondrial dysfunction. It targets cardiolipin in the inner mitochondrial membrane, stabilizing the electron transport chain. GHK-Cu has the broadest gene expression data (4,000+ genes modulated) but limited clinical aging data. Epitalon has intriguing telomerase data but lacks Western replication.

No peptide has been demonstrated to reverse biological aging in a controlled human trial. Senolytics (FOXO4-DRI) aim to clear damage (senescent cells) rather than reverse aging per se. Telomerase activators (Epitalon) address one hallmark (telomere attrition) out of twelve recognized hallmarks of aging. The realistic framing: peptides may modulate specific aging pathways, but aging is a multi-factorial process that no single intervention reverses.